21st Century Cures Act Passes Senate, Several Impacts to Device Industry

By MedTech Intelligence Staff

Several provisions are aimed at accelerating device innovation and access to medical products.

–UPDATE December, 13, 2016: Today President Obama signed the 21st Century Cures Act into law. FDA Commissioner Robert Califf, M.D. provided comments on the Act in FDA Voice (the agency’s blog): “With Cures, great progress has been made towards our shared goal of advancing regulatory science so that we can continue to speed the discovery, development, and delivery of medical products to prevent and cure disease and improve health while sustaining the evidence framework that enables assurance to the public of the safety and effectiveness of medical products.”


Last week the U.S. Senate passed the 21st Century Cures Act, a bill that supporters say will expedite the pathway way for medical technologies. Several provisions impact device manufacturers, including:

  • Enhancing combination products review. FDA is charged with identifying the responsibilities of each center within the agency in charge of reviewing medical devices, drugs and biologics.
  • Priority review for breakthrough devices.
  • Improvements to the medical device regulatory process.
  • Training staff in the review of premarket applications, applying a least burdensome approach.
  • Expansion of humanitarian device exemptions.
  • Institutional review boards charged with reviewing plans for clinical testing would not need to be in the same location as the trial.
  • Improving FDA’s scientific expertise and outreach.

Read: Five Important Facts About 21st Century Cures Act

President Obama is expected to sign the bill into law.

Related Articles

  • Sanobar Syed

    Market research and forecasting help ensure that you are investing in a device or drug that is needed and will be well received. In this article, Sanobar Syed, Associate Director of Forecasting, Market Insights and Strategies, BeiGene, highlights strategies to…

  • John Schwope

    AI not only improves data collection and analysis, it impacts which products are engaged in clinical trials, determines necessary medical criteria, helps design the trials and can even choose the best participating facilities. The result is, organizations that leverage AI…

  • Daniel Lace

    “We are honored to have Dr. Lace, who is widely recognized as one of the industry’s most trusted reimbursement experts, leading our new division. He will also support all our services as our CMO.”

  • Hand holding globe - diversity

    “Approaches to Increasing Diversity in Clinical Research and Addressing Health Inequities” offers key recommendations for device manufacturers and developers on steps they can take to increase diversity in clinical research and address health equity.

About The Author

MedTech Intelligence